Fig. 1From: Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settingsMedian best corrected visual acuity in letters (solid line) and median central macular thickness in μm (dashed line) before the initiation of treatment with ranibizumab (PR), 6 and 3 months before the switch to aflibercept, at the day of the decision to switch and every 3 months after the switch up to 36 months follow-upBack to article page